Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience

被引：0
作者：
Naoko Ishida
Kazuhiro Araki
Takehiko Sakai
Kokoro Kobayashi
Takayuki Kobayashi
Ippei Fukada
Mitsuchika Hosoda
Mitsugu Yamamoto
Kazuomi Ichinokawa
Shunji Takahashi
Takuji Iwase
Yoshinori Ito
Hiroko Yamashita
机构：
[1] Hokkaido University Hospital,Breast Surgery
[2] Cancer Institute Hospital of the Japanese Foundation for Cancer Research,Breast Medical Oncology
[3] Cancer Institute Hospital of the Japanese Foundation for Cancer Research,Surgical Oncology, Breast Oncology Center
[4] Cancer Institute Hospital of the Japanese Foundation for Cancer Research,Medical Oncology
来源：
Breast Cancer | 2016年 / 23卷
关键词：
Fulvestrant; Metastatic breast cancer; Advanced breast cancer; Postmenopausal; Endocrine therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：617 / 623
页数：6
相关论文
共 50 条
  • [1] Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience
    Ishida, Naoko
    Araki, Kazuhiro
    Sakai, Takehiko
    Kobayashi, Kokoro
    Kobayashi, Takayuki
    Fukada, Ippei
    Hosoda, Mitsuchika
    Yamamoto, Mitsugu
    Ichinokawa, Kazuomi
    Takahashi, Shunji
    Iwase, Takuji
    Ito, Yoshinori
    Yamashita, Hiroko
    BREAST CANCER, 2016, 23 (04) : 617 - 623
  • [2] Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients
    Poggio, Francesca
    Lambertini, Matteo
    Blondeaux, Eva
    Vaglica, Marina
    Levaggi, Alessia
    Pronzato, Paolo
    Del Mastro, Lucia
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (09) : 1153 - 1161
  • [3] Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study
    Xie, Yizhao
    Li, Yi
    Zhang, Yinbin
    Zhang, Shuqun
    Li, Wei
    Guan, Xiaoxiang
    Zhao, Yannan
    Gong, Chengcheng
    Hu, Xichun
    Zhang, Jian
    Cao, Enying
    Wang, Leiping
    Ge, Rui
    Wang, Biyun
    CLINICAL BREAST CANCER, 2019, 19 (03) : E452 - E458
  • [4] The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer
    Rupert Bartsch
    Brigitte Mlineritsch
    Michael Gnant
    Thomas Niernberger
    Ursula Pluschnig
    Richard Greil
    Catharina Wenzel
    Paul Sevelda
    Josef Thaler
    Margaretha Rudas
    Michael Pober
    Christoph C. Zielinski
    Guenther G. Steger
    Breast Cancer Research and Treatment, 2009, 115 : 373 - 380
  • [5] The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer
    Bartsch, Rupert
    Mlineritsch, Brigitte
    Gnant, Michael
    Niernberger, Thomas
    Pluschnig, Ursula
    Greil, Richard
    Wenzel, Catharina
    Sevelda, Paul
    Thaler, Josef
    Rudas, Margaretha
    Pober, Michael
    Zielinski, Christoph C.
    Steger, Guenther G.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) : 373 - 380
  • [6] Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
    Palumbo, Raffaella
    Sottotetti, Federico
    Quaquarini, Erica
    Gambaro, Anna
    Ferzi, Antonella
    Tagliaferri, Barbara
    Teragni, Cristina
    Licata, Luca
    Serra, Francesco
    Lapidari, Pietro
    Bernardo, Antonio
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [7] Efficacy of fulvestrant in treating postmenopausal patients with estrogen receptor-positive metastatic breast cancer and prognostic analysis
    Li, Tao
    Jiao, Lianghe
    JOURNAL OF BUON, 2021, 26 (01): : 189 - 195
  • [8] Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer
    Bundred, N
    CANCER INVESTIGATION, 2005, 23 (02) : 173 - 181
  • [9] Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective
    Marchetti, Paolo
    Maass, Nicolai
    Gligorov, Joseph
    Berger, Karin
    MacDougall, Finlay
    Montonen, Jukka
    Lewis, Jan
    BREAST, 2017, 32 : 247 - 255
  • [10] Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure A retrospective case series
    Huang, Jian
    Huang, Ping
    Shao, Xi-ying
    Sun, Yan
    Lei, Lei
    Lou, Cai-jin
    Ye, Wei-wu
    Chen, Jun-qing
    Cao, Wen-ming
    Huang, Yuan
    Zheng, Ya-bing
    Wang, Xiao-jia
    Chen, Zhan-hong
    MEDICINE, 2020, 99 (29) : E20821
12345